Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME and Mass Balance of [14C]-Darigabat in Healthy Men
NCT06435923Phase 1Completed
- Sponsor
- Cerevel Therapeutics
- Start
- May 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of darigabat in epilepsy and panic disorder, sponsored by Cerevel Therapeutics. Primary endpoints: Area Under the Concentration Time Curve from Time Zero to Infinity at Day 15, Area Under the Concentration Time Curve from Time 0 to the Time of the Last Measured Concentration at Day 15 and 10 more. Started May 2024; status: completed.
02
Drugs
darigabat
03
Conditions
epilepsypanic disorder
Beyond the preview
Go deeper on NCT06435923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06435923.